DELIVER
Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved-EF Heart Failure
Doente / População Intervenção / Exposição Comparação Desfecho
In 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.
N
6263
Desenho
Double-blind RCT
Desfecho
Worsening HF or CV death
Relevância
2
Resultado16.4 % vs 19.5 % (HR 0.82); benefit consistent across the EF spectrum.
Solomon SD, et al. N Engl J Med. 2022;387(12):1089-1098. 10.1056/NEJMoa2206286
Discussão e crítica
With EMPEROR-Preserved, made SGLT2 inhibitors the first broadly effective HFpEF therapy. Driven by HF events; mortality not significantly reduced.